Emory Discovered Drug May Take Over $3+ Billion Market Now Going to Remdesivir

Emory Discovered Drug May Take Over $3+ Billion Market Now Going to Remdesivir

EIDD-2801, the Merck drug now known as Molnupiravir, can be administered orally as a pill in an outpatient setting. The big gap that TrialSite advocates drug companies to fill in regarding COVID-19 care is the treatment at early onset of SARS-CoV-2, during the mild to moderate stage where today people diagnosed positive are simply sent home most of the time with no treatment. A number of outspoken physicians do advocate off label care. Now a drug developed at Emory’s non profit drug development organization DRIVE not only appears safe but also looks to reduce the COVID-19 infection to undetectable levels after just five day of administration, according to recent results from a Phase 2 clinical trial. Back in July, TrialSite reported on the Merck and Emory deal and suggested Merck was positioning to take out Gilead’s remdesivir lead in the market for COVID-19 antivirals. Given Gilead has generated over $3 billion in revenue in less than a year, the stakes are very large. In fact, so large TrialSite has speculated (but cannot prove) that’s one reason for Merck’s aggressive stance against its own ivermectin-based product, despite a growing number of trial results showing in...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee